Table 1.
Clinical characteristics of the entire cohort at baseline.
| Variable | N°. | |
|---|---|---|
| Age, years | 304 | 69.1 ± 9.2 |
| Sex, male | 304 | 198 (65.1) |
| Smoking habit Never Current Former Unknown |
214 |
99 (32.6) 31 (10.2) 84 (27.6) 90 (29.6) |
| Hypertension | 304 | 229 (75.3) |
| Dyslipidemia | 304 | 205 (67.4) |
| CKD | 304 | 134 (44.1) |
| Microalbuminuria Macroalbuminuria |
304 | 81 (26.6) 10 (3.3) |
| DR | 304 | 61 (20.1) |
| DN | 304 | 64 (21.1) |
| CVD | 304 | 52 (17.1) |
| Stroke | 304 | 10 (3.3) |
| HF | 304 | 5 (1.6) |
| PAD | 304 | 37 (12.2) |
| AHAs | 304 | |
| Lifestyle management | 4 (1.3) | |
| Insulin | 104 (34.2) | |
| MDI | 57 (18.7) | |
| Basal | 47 (15.5) | |
| Metformin | 261 (85.9) | |
| Sulphonylurea | 44 (14.5) | |
| DPP4i | 103 (33.9) | |
| GLP1-RA | 70 (23) | |
| SGLT2i | 47 (15.5) | |
| Pioglitazone | 20 (6.6) | |
| Acarbose | 8 (2.6) |
Abbreviations: AHA, anti-hyperglycaemic agents; CKD, chronic kidney disease; CVD, established cardiovascular disease; DN, diabetic neuropathy; DR, diabetic retinopathy; GLP1-RAs, GLP1 receptor agonists; HF, heart failure; MDI, multiple daily injections insulin therapy; PAD, peripheral artery disease.
Data are expressed as mean ± SD or frequency (%).